Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA1MK5)

• Drug Name: CYC-800 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Preclinical	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 24759764
  TTD Drug ID: DMA1MK5

Molecule-Related Drug Atlas

Drug(s) Targeting Polo-like kinase 1 (PLK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[3]
Volasertib	DMOFH1M	Acute myeloid leukaemia	2A60	Phase 3	[4]
PCM-075	DMYFRTB	Acute myeloid leukaemia	2A60	Phase 2	[5]
BI 2536	DMJSADP	Acute myeloid leukaemia	2A60	Phase 2	[2]
MK-1496	DME1ZAH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
GSK461364	DM0P729	Non-hodgkin lymphoma	2B33.5	Phase 1	[2]
TAK-960	DMN4OGH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
CYC140	DMC6PKJ	Acute myeloid leukaemia	2A60	Phase 1	[8]
Dihydropyrido pyrazinone compound 3	DM3PEUN	N. A.	N. A.	Patented	[9]
Dihydropyrido pyrazinone compound 2	DMOTG2Y	N. A.	N. A.	Patented	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Polo-like kinase 1 (PLK1)	TTIYVQP	PLK1_HUMAN	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019949)
• [2] Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
• [3] Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] J Clin Oncol 29: 2011 (suppl; abstr 3012).
• [7] TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther. 2012 Mar;11(3):700-9.
• [8] Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals.
• [9] BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.